Feasibility and safety of anti-PD1 first-line treatment of classic Hodgkin lymphoma: do we see the full picture?

2.

Armand

P

,

Zinzani

PL

,

Lee

HJ

, et al.

Five-year follow-up of KEYNOTE-087: pembrolizumab monotherapy for relapsed/refractory classical Hodgkin lymphoma

.

Blood

.

2023

;

142

(

10

):

878

-

886

.

3.

Borchmann

P

,

Ferdinandus

J

,

Schneider

G

, et al;

German Hodgkin Study Group

Swiss Group for Clinical Cancer Research

Arbeitsgemeinschaft Medikamentöse Tumortherapie

Nordic Lymphoma Group

Australasian Leukaemia and Lymphoma Group

.

Assessing the efficacy and tolerability of PET-guided BrECADD versus eBEACOPP in advanced-stage, classical Hodgkin lymphoma (HD21): a randomised, multicentre, parallel, open-label, phase 3 trial

.

Lancet

.

2024

;

404

(

10450

):

341

-

352

.

4.

Sasse

S

,

Bröckelmann

PJ

,

Goergen

H

, et al.

Long-term follow-up of contemporary treatment in early-stage Hodgkin lymphoma: updated analyses of the German Hodgkin Study Group HD7, HD8, HD10, and HD11 Trials

.

J Clin Oncol

.

2017

;

35

(

18

):

1999

-

2007

.

5.

Ansell

SM

,

Radford

J

,

Connors

JM

, et al;

ECHELON-1 Study Group

.

Overall survival with brentuximab vedotin in stage III or IV Hodgkin's lymphoma

.

N Engl J Med

.

2022

;

387

(

4

):

310

-

320

.

6.

Bröckelmann

PJ

.

Hodgkin lymphoma: great progress with room for improvement

.

Nat Rev Clin Oncol

.

2025

;

22

(

6

):

379

-

381

.

7.

Kreissl

S

,

Goergen

H

,

Buehnen

I

, et al;

German Hodgkin Study Group

.

PET-guided eBEACOPP treatment of advanced-stage Hodgkin lymphoma (HD18): follow-up analysis of an international, open-label, randomised, phase 3 trial

.

Lancet Haematol

.

2021

;

8

(

6

):

e398

-

e409

.

8.

Bröckelmann

PJ

,

Müller

H

,

Fuchs

M

, et al.

Correlation between progression-free and overall survival in patients with Hodgkin lymphoma: a comprehensive analysis of individual patient data from randomized German Hodgkin Study Group (GHSG) trials

.

Ann Oncol

.

2025

;

36

(

4

):

393

-

402

.

9.

Kuderer

NM

,

Desai

A

,

Lustberg

MB

,

Lyman

GH

.

Mitigating acute chemotherapy-associated adverse events in patients with cancer

.

Nat Rev Clin Oncol

.

2022

;

19

(

11

):

681

-

697

.

10.

Lustberg

MB

,

Kuderer

NM

,

Desai

A

,

Bergerot

C

,

Lyman

GH

.

Mitigating long-term and delayed adverse events associated with cancer treatment: implications for survivorship

.

Nat Rev Clin Oncol

.

2023

;

20

(

8

):

527

-

542

.

11.

Tison

A

,

Garaud

S

,

Chiche

L

,

Cornec

D

,

Kostine

M

.

Immune-checkpoint inhibitor use in patients with cancer and pre-existing autoimmune diseases

.

Nat Rev Rheumatol

.

2022

;

18

(

11

):

641

-

656

.

12.

Goodman

RS

,

Lawless

A

,

Woodford

R

, et al.

Extended follow-up of chronic immune-related adverse events following adjuvant anti-PD-1 therapy for high-risk resected melanoma

.

JAMA Netw Open

.

2023

;

6

(

8

):

e2327145

.

13.

Jayathilaka

B

,

Mian

F

,

Franchini

F

,

Au-Yeung

G

,

IJzerman

M

.

Cancer and treatment specific incidence rates of immune-related adverse events induced by immune checkpoint inhibitors: a systematic review

.

Br J Cancer

.

2025

;

132

(

1

):

51

-

57

.

14.

Gougis

P

,

Jochum

F

,

Abbar

B

, et al.

Clinical spectrum and evolution of immune-checkpoint inhibitors toxicities over a decade-a worldwide perspective

.

EClinicalMedicine

.

2024

;

70

:

102536

.

15.

Postow

MA

,

Sidlow

R

,

Hellmann

MD

.

Immune-related adverse events associated with immune checkpoint blockade

.

N Engl J Med

.

2018

;

378

(

2

):

158

-

168

.

16.

Yin

Q

,

Wu

L

,

Han

L

, et al.

Immune-related adverse events of immune checkpoint inhibitors: a review

.

Front Immunol

.

2023

;

14

:

1167975

.

17.

Johnson

DB

,

Nebhan

CA

,

Moslehi

JJ

,

Balko

JM

.

Immune-checkpoint inhibitors: long-term implications of toxicity

.

Nat Rev Clin Oncol

.

2022

;

19

(

4

):

254

-

267

.

18.

Naidoo

J

,

Murphy

C

,

Atkins

MB

, et al.

Society for Immunotherapy of Cancer (SITC) consensus definitions for immune checkpoint inhibitor-associated immune-related adverse events (irAEs) terminology

.

J Immunother Cancer

.

2023

;

11

(

3

):

e006398

.

19.

Owen

CN

,

Bai

X

,

Quah

T

, et al.

Delayed immune-related adverse events with anti-PD-1-based immunotherapy in melanoma

.

Ann Oncol

.

2021

;

32

(

7

):

917

-

925

.

20.

Schulz

TU

,

Zierold

S

,

Sachse

MM

, et al.

Persistent immune-related adverse events after cessation of checkpoint inhibitor therapy: prevalence and impact on patients' health-related quality of life

.

Eur J Cancer

.

2022

;

176

:

88

-

99

.

21.

Iyer

PC

,

Cabanillas

ME

,

Waguespack

SG

, et al.

Immune-related thyroiditis with immune checkpoint inhibitors

.

Thyroid

.

2018

;

28

(

10

):

1243

-

1251

.

22.

Mosaferi

T

,

Tsai

K

,

Sovich

S

, et al.

Optimal thyroid hormone replacement dose in immune checkpoint inhibitor-associated hypothyroidism is distinct from Hashimoto's Thyroiditis

.

Thyroid

.

2022

;

32

(

5

):

496

-

504

.

23.

Allen

PB

,

Savas

H

,

Evens

AM

, et al.

Pembrolizumab followed by AVD in untreated early unfavorable and advanced-stage classical Hodgkin lymphoma

.

Blood

.

2021

;

137

(

10

):

1318

-

1326

.

24.

Allen

PB

,

Lu

X

,

Chen

Q

, et al.

Sequential pembrolizumab and AVD are highly effective at any PD-L1 expression level in untreated Hodgkin lymphoma

.

Blood Adv

.

2023

;

7

(

12

):

2670

-

2676

.

25.

Bröckelmann

PJ

,

Goergen

H

,

Keller

U

, et al.

Efficacy of nivolumab and AVD in early-stage unfavorable classic Hodgkin lymphoma: the randomized phase 2 German Hodgkin Study Group NIVAHL Trial

.

JAMA Oncol

.

2020

;

6

(

6

):

872

-

880

.

26.

Bröckelmann

PJ

,

Bühnen

I

,

Meissner

J

, et al.

Nivolumab and doxorubicin, vinblastine, and dacarbazine in early-stage unfavorable Hodgkin lymphoma: final analysis of the randomized German Hodgkin Study Group Phase II NIVAHL trial

.

J Clin Oncol

.

2023

;

41

(

6

):

1193

-

1199

.

27.

Bröckelmann

PJ

,

Bühnen

I

,

Herhaus

P

, et al.

Quality of life with nivolumab and AVD first-line treatment in Hodgkin lymphoma: patient-reported outcomes from the phase II GHSG Nivahl trial [abstract]

.

Blood

.

2023

;

142

(

suppl 1

):

1710

.

28.

Dickinson

M

,

Berkahn

L

,

Trotman

J

, et al.

P1066: pembrolizumab monotherapy as a first therapy for Hodgkin Lymphoma is deliverable in older or ABVD ineligible patients, does not preclude subsequent therapy, and provides adequate survival

.

Hemasphere

.

2023

;

7

(

S3

):

e691267e

.

29.

Dickinson

MJ

,

Trotman

J

,

Berkahn

L

, et al.

Pembrolizumab as first therapy for Hodgkin Lymphoma is deliverable in older or ABVD-ineligible patients, allows subsequent therapy, and gives adequate survival

.

Hematological Oncol

.

2023

;

41

(

S2

):

160

-

161

.

30.

Dickinson

M

. Pembrolizumab Monotherapy for Older/ABVD-Ineligible Patients With Hodgkin Lymphoma.

VJHEMONC

;

2023

Accessed 6 November 2025. https://www.vjhemonc.com/video/kcqjhmelcpe-pembrolizumab-monotherapy-for-olderabvd-ineligible-patients-with-hodgkin-lymphoma/.

31.

Friedberg

JW

,

Bordoni

R

,

Patel-Donnelly

D

, et al.

Brentuximab vedotin with dacarbazine or nivolumab as frontline cHL therapy for older patients ineligible for chemotherapy

.

Blood

.

2024

;

143

(

9

):

786

-

795

.

32.

Herrera

AF

,

LeBlanc

M

,

Castellino

SM

, et al.

Nivolumab+AVD in advanced-stage classic Hodgkin's lymphoma

.

N Engl J Med

.

2024

;

391

(

15

):

1379

-

1389

.

33.

Rutherford

SC

,

Li

H

,

Herrera

AF

, et al.

Nivolumab-AVD versus brentuximab vedotin-AVD in older patients with advanced-stage classic Hodgkin lymphoma enrolled on S1826

.

J Clin Oncol

.

2025

;

43

(

27

):

2968

-

2973

.

34.

Lazarovici

J

,

Amorim

S

,

Bouabdallah

K

, et al.

Nivolumab first-line therapy for elderly, frail Hodgkin lymphoma patients: Niviniho, a Lysa phase II study [abstract]

.

Blood

.

2021

;

138

(

suppl 1

):

232

.

35.

Lee

HJ

,

Ramchandren

R

,

Friedman

J

, et al.

Brentuximab vedotin, nivolumab, doxorubicin, and dacarbazine for advanced-stage classical Hodgkin lymphoma

.

Blood

.

2025

;

145

(

3

):

290

-

299

.

36.

Lynch

RC

,

Ujjani

CS

,

Poh

C

, et al.

Concurrent pembrolizumab with AVD for untreated classic Hodgkin lymphoma

.

Blood

.

2023

;

141

(

21

):

2576

-

2586

.

37.

Kuczmarski

TM

,

Ujjani

CS

,

Poh

C

, et al.

Potential delayed immune-related adverse events in patients treated with frontline pembrolizumab + AVD for classic Hodgkin lymphoma [abstract]

.

Blood

.

2024

;

144

(

suppl 1

):

1667

.

38.

Ramchandren

R

,

Domingo-Domènech

E

,

Rueda

A

, et al.

Nivolumab for newly diagnosed advanced-stage classic Hodgkin lymphoma: safety and efficacy in the phase II CheckMate 205 study

.

J Clin Oncol

.

2019

;

37

(

23

):

1997

-

2007

.

39.

Torka

P

,

Feldman

T

,

Savage

KJ

, et al.

Phase II trial of nivolumab plus doxorubicin, vinblastine, dacarbazine as frontline therapy in older adults with Hodgkin lymphoma

.

J Clin Oncol

.

2025

;

43

(

8

):

985

-

993

.

40.

Bröckelmann

PJ

,

Cliff

ERS

,

Iacoboni

G

, et al.

Beyond maximum grade: tolerability of immunotherapies, cellular therapies, and targeted agents in haematological malignancies

.

Lancet Haematol

.

2025

;

12

(

6

):

e470

-

e481

.

41.

Zhang

Z

,

Sharma

R

,

Hamad

L

,

Riebandt

G

,

Attwood

K

.

Incidence of diabetes mellitus in patients treated with immune checkpoint inhibitors (ICI) therapy - a comprehensive cancer center experience

.

Diabetes Res Clin Pract

.

2023

;

202

:

110776

.

42.

Ferdinandus

J

,

Schneider

G

,

Moccia

A

, et al.

Fertility in patients with advanced-stage classic Hodgkin lymphoma treated with BrECADD versus eBEACOPP: a secondary analysis of the multicentre, randomised, parallel, open-label, phase 3 HD21 trial

.

Lancet Oncol

.

2025

;

26

(

8

):

1081

-

1090

.

43.

Bröckelmann

PJ

,

Bühnen

I

,

Herhaus

P

, et al.

Fertility and gonadal function after first-line treatment with nivolumab-AVD in Hodgkin lymphoma patients: an analysis from the phase II GHSG Nivahl trial [abstract]

.

Blood

.

2023

;

142

(

suppl 1

):

4456

.

44.

Winship

AL

,

Alesi

LR

,

Sant

S

, et al.

Checkpoint inhibitor immunotherapy diminishes oocyte number and quality in mice

.

Nat Cancer

.

2022

;

3

(

8

):

1

-

13

.

45.

Özdemir

BC

.

Immune checkpoint inhibitor-related hypogonadism and infertility: a neglected issue in immuno-oncology

.

J Immunother Cancer

.

2021

;

9

(

2

):

e002220

.

46.

Ferdinandus

J

,

Kaul

H

,

Fosså

A

, et al.

PET-guided Brecadd in older patients with advanced-stage classic Hodgkin lymphoma: results of the phase 2 part of the GHSG HD21 trial [abstract]

.

Blood

.

2024

;

144

(

suppl 1

):

568

.